Blueprint Medicines (BPMC) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[5], including 1 Phase 3[1], 3 Phase 2[2], 1 Phase 1[3], 1 Phase 4[4].
Trial NCT04910685[6] evaluates Elenestinib in Indolent Systemic Mastocytosis with a target enrollment of 534 participants.
No Form 4 insider filings for BPMC were recorded at the SEC in the past 30 days[7].